Related Experiment Video
Updated: Sep 11, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.6K
Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma
Jahnavi Chaudhari1,2, Nikesh N Shah3
1Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA.
Cancers
|August 14, 2025
Summary
Diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL), is the most common type. Understanding its characteristics is crucial for developing effective treatment strategies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Diffuse large B-cell lymphoma (DLBCL) represents the most frequent and aggressive subtype of non-Hodgkin lymphoma (NHL).
- DLBCL is characterized by rapid proliferation of malignant B-cells, necessitating urgent and effective therapeutic interventions.
Purpose of the Study:
- To elucidate the key pathological and clinical features of DLBCL.
- To provide a comprehensive overview of current understanding and research directions in DLBCL.
Main Methods:
- Review of existing literature on DLBCL.
- Analysis of epidemiological data and clinical trial outcomes.
- Exploration of molecular and genetic drivers of DLBCL.
Main Results:
- DLBCL exhibits significant heterogeneity in its molecular subtypes, impacting patient prognosis.
- Current treatment regimens, including chemoimmunotherapy, show variable efficacy across different DLBCL patient groups.
- Emerging research focuses on targeted therapies and immunotherapy for relapsed or refractory DLBCL.
Conclusions:
- DLBCL remains a significant clinical challenge due to its aggressive nature and heterogeneity.
- Further research into molecular mechanisms and personalized treatment approaches is essential for improving patient outcomes in DLBCL.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
01:30Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509